Latest Regulatory Engagement News

Neurizon Therapeutics has commenced dosing in a major Phase 2/3 trial of its lead drug NUZ-001 for ALS, marking a critical step in advancing treatment options for this devastating disease.

Critical Resources Limited highlights significant progress in its lithium and gold projects across Canada and New Zealand, alongside pioneering work in next-generation solid-state lithium-ion batteries.

NeuroScientific Biopharmaceuticals reported a $1.7 million loss for the half-year ending December 2025, driven by ongoing R&D investments. The company progressed clinical treatments for Crohn’s disease and glaucoma, alongside key leadership appointments and strategic partnerships.

Island Pharmaceuticals reports a 213.8% increase in half-year loss to $4.81 million, driven by strategic acquisition and clinical development investments. The company advances its antiviral portfolio with Galidesivir and ISLA-101, supported by strong US regulatory engagement and a $9 million capital raise.

RocketDNA Ltd reported a 6% increase in revenue to AUD 76.83 million for the year ended 31 December 2025, expanding its autonomous drone footprint across Australia and Africa while securing major mining contracts.

Greenwing Resources has significantly enhanced the economics of its Que River Project following a sharp rise in key metal prices, nearly doubling projected cash flows and advancing a two-stage development plan.

Australian Vanadium Limited has broadened its Optimised Feasibility Study to include high purity vanadium products aimed at aerospace, defence, and advanced manufacturing sectors, aligning with evolving critical minerals demand without delaying project timelines.

Jameson Resources has marked significant progress in advancing its Crown Mountain steelmaking coal project, doubling its pre-tax NPV to US$942 million and moving closer to final environmental approvals and development permits expected by the end of 2026.

SkyCity Entertainment Group posted a solid half-year profit increase to NZD 12.1 million despite a slight revenue dip, bolstered by a major equity raise and a clean bill on its Adelaide casino licence.

Paradigm Biopharmaceuticals has drawn down US$5 million from its Convertible Note Facility to fund the next phase of its global Phase 3 trial for knee osteoarthritis treatment, marking a key step as patient recruitment nears 50%.

Alicanto Minerals has completed its acquisition of the Mt Henry Gold Project in Western Australia, setting the stage for an ambitious 50,000-metre drilling campaign aimed at expanding the existing 915,000-ounce gold resource.

St Barbara Limited has expanded its Nova Scotia exploration portfolio with 44 new targets near its 15-Mile Processing Hub, aiming to extend the mine life beyond 11 years. The company has acquired 174 exploration licences and plans extensive drilling and sampling in 2026.